Tyra Biosciences Q2 net loss widens to $28.1 mln

Reuters

Aug 15

<a href="https://laohu8.com/S/TYRA">Tyra Biosciences</a> <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens to $28.1 mln

Overview

Tyra Biosciences Q2 net loss widens to $28.1 mln from $18.7 mln last year
Basic EPS beats analyst expectations, despite increased R&D and G&A expenses
Co dosed first patient in SURF302 Phase 2 bladder cancer study

Outlook

Tyra expects cash reserves to support operations through at least 2027
Company anticipates Phase 2 readouts in SURF302 and BEACH301
Tyra sees significant opportunity in FGFR3-targeted therapies for bladder cancer
Company plans to dose first child in BEACH301 study in 3Q 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income		-$28.10 mln
Q2 Basic EPS	Beat	-$0.47	-$0.53 (8 Analysts)
Q2 Operating Income	Beat	-$31.45 mln	-$33.50 mln (8 Analysts)
Q2 Operating Expenses		$31.45 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Tyra Biosciences Inc is $30.00, about 64.2% above its August 13 closing price of $10.75

Press Release: ID:nPnc2yZXMa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559964354"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559964354\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559964354?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559964354","market":"nz","top_or_hot":-1,"title":"Tyra Biosciences Q2 net loss widens to $28.1 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/TYRA\">Tyra Biosciences</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens to $28.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Tyra Biosciences Q2 net loss widens to $28.1 mln from $18.7 mln last year</p></li><li><p>Basic EPS beats analyst expectations, despite increased R&amp;D and G&amp;A expenses</p></li><li><p>Co dosed first patient in SURF302 Phase 2 bladder cancer study</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tyra expects cash reserves to support operations through at least 2027</p></li><li><p>Company anticipates Phase 2 readouts in SURF302 and BEACH301</p></li><li><p>Tyra sees significant opportunity in FGFR3-targeted therapies for bladder cancer</p></li><li><p>Company plans to dose first child in BEACH301 study in 3Q 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$28.10 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td><p>Beat</p></td><td><p>-$0.47</p></td><td><p>-$0.53 (8 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Beat</p></td><td><p>-$31.45 mln</p></td><td><p>-$33.50 mln (8 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$31.45 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Tyra Biosciences Inc is $30.00, about 64.2% above its August 13 closing price of $10.75</p></li></ul><p>Press Release: <span>ID:nPnc2yZXMa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tyra Biosciences Q2 net loss widens to $28.1 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTyra Biosciences Q2 net loss widens to $28.1 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-15 04:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/TYRA\">Tyra Biosciences</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens to $28.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Tyra Biosciences Q2 net loss widens to $28.1 mln from $18.7 mln last year</p></li><li><p>Basic EPS beats analyst expectations, despite increased R&amp;D and G&amp;A expenses</p></li><li><p>Co dosed first patient in SURF302 Phase 2 bladder cancer study</p></li></ul><p><span>Outlook</span></p><ul><li><p>Tyra expects cash reserves to support operations through at least 2027</p></li><li><p>Company anticipates Phase 2 readouts in SURF302 and BEACH301</p></li><li><p>Tyra sees significant opportunity in FGFR3-targeted therapies for bladder cancer</p></li><li><p>Company plans to dose first child in BEACH301 study in 3Q 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$28.10 mln</p></td><td></td></tr><tr><td><p>Q2 Basic EPS</p></td><td><p>Beat</p></td><td><p>-$0.47</p></td><td><p>-$0.53 (8 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Beat</p></td><td><p>-$31.45 mln</p></td><td><p>-$33.50 mln (8 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$31.45 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Tyra Biosciences Inc is $30.00, about 64.2% above its August 13 closing price of $10.75</p></li></ul><p>Press Release: <span>ID:nPnc2yZXMa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nPLX3EE493:1","article_id":"2559964354","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559964354","pubTimestamp":1755202779,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tyra Biosciences Q2 net loss widens to $28.1 mlnOverviewTyra Biosciences Q2 net loss widens to $28.1 mln from $18.7 mln last yearBasic EPS beats analyst expectations, despite increased R&D and G&A exp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TYRA":"Tyra Biosciences, Inc."},"translate_title":"Tyra Biosciences第二季度净亏损扩大至2810万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYRA":0.9},"content_text":"Tyra Biosciences Q2 net loss widens to $28.1 mlnOverviewTyra Biosciences Q2 net loss widens to $28.1 mln from $18.7 mln last yearBasic EPS beats analyst expectations, despite increased R&D and G&A expensesCo dosed first patient in SURF302 Phase 2 bladder cancer studyOutlookTyra expects cash reserves to support operations through at least 2027Company anticipates Phase 2 readouts in SURF302 and BEACH301Tyra sees significant opportunity in FGFR3-targeted therapies for bladder cancerCompany plans to dose first child in BEACH301 study in 3Q 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ2 Net Income-$28.10 mlnQ2 Basic EPSBeat-$0.47-$0.53 (8 Analysts)Q2 Operating IncomeBeat-$31.45 mln-$33.50 mln (8 Analysts)Q2 Operating Expenses$31.45 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Tyra Biosciences Inc is $30.00, about 64.2% above its August 13 closing price of $10.75Press Release: ID:nPnc2yZXMa(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}